| Year |
Citation |
Score |
| 2019 |
Perez K, Chan J. Treatment of Gastroenteropancreatic Neuroendocrine Tumors. Surgical Pathology Clinics. 12: 1045-1053. PMID 31672293 DOI: 10.1016/J.Path.2019.08.011 |
0.335 |
|
| 2019 |
Kulke MH, Benson AB, Dasari A, Huynh L, Cai B, Totev T, Roesner N, Duh MS, Neary MP, Maurer VE, Shih BE, Dagohoy CG, Chan J, Bergsland EK. Real-World Treatment Patterns and Clinical Outcomes in Advanced Gastrointestinal Neuroendocrine Tumors (GI NET): A Multicenter Retrospective Chart Review Study. The Oncologist. PMID 30606883 DOI: 10.1634/Theoncologist.2018-0519 |
0.315 |
|
| 2018 |
Shah MH, Goldner WS, Halfdanarson TR, Bergsland E, Berlin JD, Halperin D, Chan J, Kulke MH, Benson AB, Blaszkowsky LS, Eads J, Engstrom PF, Fanta P, Giordano T, He J, et al. NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018. Journal of the National Comprehensive Cancer Network : Jnccn. 16: 693-702. PMID 29891520 DOI: 10.6004/Jnccn.2018.0056 |
0.316 |
|
| 2015 |
Urgoiti GR, Lawn S, Scott J, Easaw JC, Kenchappa R, Taylor JW, Paleologos N, Schiff D, Chan J, Forsyth PAJ. Evaluation of p75 expression and patterns of recurrence in patients with malignant gliomas treated with bevacizumab. Journal of Clinical Oncology. 33. DOI: 10.1200/Jco.2015.33.15_Suppl.E13006 |
0.317 |
|
| 2015 |
Alshehri M, Ahn BY, Wang X, Tanveer S, Chan J, Senger DL, Robbins SM. Abstract A32: Cell autonomous and cell non-autonomous roles of p75 neurotrophin receptor (p75NTR) in glioma invasion Brain. 75. DOI: 10.1158/1538-7445.Brain15-A32 |
0.36 |
|
| 2015 |
Urgoiti GR, Lawn S, Scott J, Easaw J, Kenchappa R, Taylor J, Paleologos N, Schiff D, Chan J, Forsyth P. MTR-13EVALUATION OF p75 EXPRESSION AND PATTERNS OF RECURRENCE IN PATIENTS WITH MALIGNANT GLIOMAS TREATED WITH BEVACIZUMAB Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov219.13 |
0.306 |
|
| 2014 |
Chan J, Kulke M. Targeting the mTOR signaling pathway in neuroendocrine tumors. Current Treatment Options in Oncology. 15: 365-79. PMID 25092520 DOI: 10.1007/S11864-014-0294-4 |
0.362 |
|
| 2014 |
Buczkowicz P, Hoeman C, Rakopoulos P, Pajovic S, Letourneau L, Dzamba M, Morrison A, Lewis P, Bouffet E, Bartels U, Zuccaro J, Agnihotri S, Ryall S, Barszczyk M, Chornenkyy Y, ... ... Chan J, et al. Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nature Genetics. 46: 451-6. PMID 24705254 DOI: 10.1038/Ng.2936 |
0.329 |
|
| 2014 |
Lawn S, Dixit R, Chan J. Pm-08Investigating The Determinants Of Gbm Subtypes Using Novel Mouse Models Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou268.8 |
0.302 |
|
| 2014 |
Kenchappa R, Lawn S, Krishna N, Qu X, Fenstermacher D, Chan J, Forsyth P. CS-14 * NEUROTROPHIN RECEPTORS TrkB AND TrkC ARE REQUIRED FOR SURVIVAL OF BRAIN TUMOR INITIATING CELLS Neuro-Oncology. 16: v54-v54. DOI: 10.1093/Neuonc/Nou242.14 |
0.324 |
|
| 2013 |
Strosberg JR, Chan JA, Ryan DP, Meyerhardt JA, Fuchs CS, Abrams T, Regan E, Brady R, Weber J, Campos T, Kvols LK, Kulke MH. A multi-institutional, phase II open-label study of ganitumab (AMG 479) in advanced carcinoid and pancreatic neuroendocrine tumors. Endocrine-Related Cancer. 20: 383-90. PMID 23572164 DOI: 10.1530/Erc-12-0390 |
0.33 |
|
| 2012 |
Brognaro E, Ghods A, Feinstein D, Glick R, Connolly KJ, Meetze K, Boudrow A, Gyuris J, Han M, Hingtgen S, Figueiredo J, Farrar C, Farrar C, Deubgen M, Martinez-Quintanilla J, ... ... Chan J, et al. LAB-TUMOR MODELS (IN VIVO/IN VITRO) Neuro-Oncology. 14: vi160-vi164. DOI: 10.1093/Neuonc/Nos241 |
0.308 |
|
| 2011 |
Roldán G, Chan J, Eliasziw M, Cairncross JG, Forsyth PA. Leptomeningeal disease in oligodendroglial tumors: a population-based study. Journal of Neuro-Oncology. 104: 811-5. PMID 21373968 DOI: 10.1007/S11060-011-0551-3 |
0.347 |
|
| 2010 |
Lun X, Chan J, Zhou H, Sun B, Kelly JJ, Stechishin OO, Bell JC, Parato K, Hu K, Vaillant D, Wang J, Liu TC, Breitbach C, Kirn D, Senger DL, et al. Efficacy and safety/toxicity study of recombinant vaccinia virus JX-594 in two immunocompetent animal models of glioma. Molecular Therapy : the Journal of the American Society of Gene Therapy. 18: 1927-36. PMID 20808290 DOI: 10.1038/Mt.2010.183 |
0.318 |
|
| 2010 |
Goutagny S, Yang HW, Zucman-Rossi J, Chan J, Dreyfuss JM, Park PJ, Black PM, Giovannini M, Carroll RS, Kalamarides M. Genomic profiling reveals alternative genetic pathways of meningioma malignant progression dependent on the underlying NF2 status. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 4155-64. PMID 20682713 DOI: 10.1158/1078-0432.Ccr-10-0891 |
0.321 |
|
| 2009 |
MacConaill LE, Campbell CD, Kehoe SM, Bass AJ, Hatton C, Niu L, Davis M, Yao K, Hanna M, Mondal C, Luongo L, Emery CM, Baker AC, Philips J, Goff DJ, ... ... Chan J, et al. Profiling critical cancer gene mutations in clinical tumor samples. Plos One. 4: e7887. PMID 19924296 DOI: 10.1371/Journal.Pone.0007887 |
0.319 |
|
| 2007 |
Cargioli TG, Ugur HC, Ramakrishna N, Chan J, Black PM, Carroll RS. Establishment of an in vivo meningioma model with human telomerase reverse transcriptase. Neurosurgery. 60: 750-9; discussion 75. PMID 17415213 DOI: 10.1227/01.Neu.0000255397.00410.8F |
0.333 |
|
| Show low-probability matches. |